Adjuvant chemotherapy following surgery in the management of uterine sarcomas

Objective: The aim of this study was to investigate the use of imaging tools in the diagnosis of uterine sarcomas, and to evaluate the effect of the adjuvant chemotherapy for uterine sarcomas.

Patients and methods: The data of 29 patients with uterine sarcomas who received cytostatic polychemotherapy between 1990 and 2000 at the Oncological Division of the Ist Department of Obstetrics and Gynecology, Semmelweis University were evaluated by the authors. Symptoms leading to diagnosis and methods of diagnosis were examined. Vascular changes shown by two-dimensional, color and pulsed Doppler ultrasonography were observed. For staging the currently accepted FIGO method was adopted. Most of the patients underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH & BSO). In each case we administered adjuvant combination chemotherapy according to the CYVADIC-protocol. The effect of adjuvant chemotherapy was evaluated.

Results: Six patients had Stage I, ten had Stage II, 11 had Stage III, and two had Stage IV disease. The mean age of the patients was 53.6 years with a range of 22 to 77 years. Histopathologic distribution included nine leiomyosarcomas (LMS), 13 mixed mesodermal sarcomas (MMS), and seven endometrial stromal sarcomas (ESS). Although most patients experienced neutropenia following cytotoxic chemotherapy, other non-hematologic adverse effects were easy to control. The average progression-free interval was 22.14 months, in which no significant difference was found between the histologic types. Different stages showed highly varied responses: surprisingly, patients in Stage IV with lung metastases were documented to have the longest progression-free survival. The three-year survival rate for all stages was demonstrated in 34.4% of cases. Patients with progressive disease had an average survival period of 4.4 months.

Conclusions: These findings suggest that adjuvant cytostatic therapy for patients with distant metastasis confined to a single organ may produce better results than expected.

Uterine sarcoma; Cytostatic treatment, CYVADIC

[1] Olah K.S., Gee H., Blunt S., Dunn J.A., Kelly K., Chan K.K.: "Retrospective analysis of 3 I 8 cases of uterine sarcoma". Eur. J. Cancer, 1991, 27, 1095

[2] Kudelka A.P., de Leon C.G., Edwards C.L., Kavanagh J.J.: "Tumors of the uterine corpus". In: Pazdur R. (ed.), "Medical Oncology", New York, Huntington, 1993, 278.

[3] Jereczek B., Jassem J., Kobierska A.: "Sarcoma of uterus A clinical study of 42 patients". Arch. Gynecol. Obstet., 1996, 258, 171.

[4] Leibsohn S., D'Ablaing G., Mishell D. Jr., Schlaerth J.B.: "Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas". Am. J. Obstet. Gynecol., 1990, 162, 968.

[5] Larson B., Silfversward C., Nilsson B., Pettersson F.: "Endometrial stromal sarcoma of the uterus. A clinical and histopathological study. The Radiumhemmet series 1936-1981 ". Eur. J. Obstet. Gynecol. Reprod. Biol., 1990, 35, 239.

[6] Gilbert H.A., Kagan A.R., Lagasse L., Jacobs M.R., Tawa T.: "The value of radiation therapy in uterine sarcoma". Obstet. Gynecol., 1975, 45, 84.

[7] Gerszten K., Faul C., Kounelis S., Huang Q., Kelley J., Jones M.W.:'The impact of adjuvant radiotherapy on carcinosarcoma of the uterus". Gynecol. Oneal., 1998, 68, 8.

[8] Hannigan E.V., Freedman R.S., Rutledge F.N.: "Adjuvant chemotherapy in early uterine sarcoma". Gynecol. Oneal., 1983, 15, 56.

[9] Omura G.A., Blessing J.A., Major F., Lifsh叩S., Ehrlich C.E., Mangan C. et al.: "A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study". J. Clin. Oneal., 1985, 3, 1240.

[10] Yap B.S., Baker L.H., Sinkovics J.G., Rivkin S.E., Bottomley R., Thigpen T. et. al.: "Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas". Cancer Treat. Rep., 1980, 64, 93.

[11] Piver M.S., De Eulis T.G., Lele S.B.: "Cyclophosphamide, vincristine, adriamycin, and dimethyl-triazeno-imidazole carboxamide (CYVADIC) for sarcomas of the female genital tract". Gynecol. Oneal., 1982, 14, 319.

[12] Rose P.G., Boutselis J.G., Sachs L.: "Adjuvant therapy for stage I uterine sarcoma". Am. J. Obstet. Gynecol., 1987, 156, 660.

[13] Piver M.S., Rose P.G.: "Advanced uterine sarcoma; response to chemotherapy". Eur. J. Gynaec. Oncol., 1988, 9, 124.

[14] Piver M.S., Lele S.B., Marchetti D.L., Emrich L.J.: "Effect of adjuvant chemotherapy on time to recurrence and survival of stage I uterine sarcomas". J. Surg. Oneal., 1988 (suppl.), 38, 233.

[15] Adams M.: "Chemotherapy of gynaecological sarcomata". In Bosze P. (ed.) Proc. of the European School of Oncology, Budapest, 1993.

[16] Olah K.S., Dunn J.A., Gee H.: "Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors: the results of retrospective study of 423 cases of uterine sarcoma". Br. J. Obstet. Gynecol., 1992, 99, 590.

[17] Dinh T., Woodruff J.D.: "Leiomyosarcoma of the uterus". Am. J. Obstet. Gynecol., 1982, 144, 817.

[18] Kahanpaa K.V., Wahlstrom T., Grohn P., Heinonen E., N1emmen U., Widholm 0.: "Sarcomas of the uterus: A clinicopathologic study of 119 patients". Obstet. Gynecol., 1986, 67, 417.

[19] Tepper R., Altaras M., Goldberger S., Zale! Y., Cordoba M., Beyth Y.: "Color doppler ultrasonographic findings in low and high grade endometrial stromal sarcomas". J. Ultrasound Med., 1994, 13, 817.

[20] Chen C.D., Huang C.C., Wu C.C., Tseng G.C., Lin G.J., Hsieh C. Y. et al.: "Sonographic characteristics in low-grade endometrial stromal sarcoma: a report of two cases". J. Ultrasound Med., 1995, 14, 165.

[21] Kurjak A., Kupesic S., Shalan H., Jukic S., Kosuta D., Ilijas M.: "Uterine sarcoma: a report of 10 cases studied by transvaginalk color and pulsed Doppler sonography". Gynecol. Oneal., 1995, 59, 342.

[22] Szanthó A., Szabo I., Demeter A., Papp Z.: "Clinical experience with uterine sarcoma: sonographic characteristics and treatment". Int. J. Gynecol. Cancer, 1999, 9 (suppl. 1), 142.

[23] Szabo I., S瓜nth6 A., Csabay L., Csap6 Zs., Szirmai K., Papp Z.: "Color Doppler ultrasonography in the differentiation of uterine sarcomas from uterine leiomyomas". Eur. J. Gynaecol. Oncol., 2002, 23, 29.

[24] Berchuck A.B., Rubin S.C., Hoskins W.J., Saigo P.E., Pierce V.K., Lewis J.L.: "Treatment of Uterine Leiomyosarcoma". Obstet. Gynecol., 1988, 71, 845.

[25) Muss H.B., Bundy B., DiSaia P.J., Homesley H.D., Fowler W.C., Creasman W., Yordan E.: "Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecolo gic Oncology Group)". Cancer, 1985, 55, 1648.

[26] Omura G.A., Major F.J., Blessing J.A.: "A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas". Cancer, 1983, (suppl. 2), 626.

[27] Fukunishi H., Yukimura N., Takeuchi S., Kitazawa S.: "Uterine myxoid leiomyosarcoma and CY VADIC-etoposide therapy". Int. J. Gynaecol. Obstet., 1994, 46, 321.

[28] Hempling R.E., Piver M.S., Baker T.R.: "Impact on progressionfree survival of adjuvant cyclophosphamide, vincristine, doxorubicin (adriamycin), and dacarbazine (CYVADIC) chemotherapy for stage I uterine sarcoma. A prospective trial". Am. J. of Clin Oncol., 1995, 18, 282.

[29] Sutton G.P., Blessing J.A., Ball H.: "Phase II trial of paclitaxel m leiomyosarcoma of the uterus: Gynecologic Oncology Group study". Gynecol. Oncol., 1999, 74, 346.